- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

NICE commits to greater flexibility in its evaluation of new health technologies

The National Institute for Health and Care Excellence (NICE) is changing the way it evaluates medicines and other health technologies for use in the NHS.

The changes will come into effect early next month for new evaluations and will give patients earlier access to innovative new treatments by allowing greater flexibility over decisions about value for money and consideration of a broader evidence base.

They cover how topics are chosen (topic selection), the steps and stages in each evaluation (processes), and how evidence is collected and considered (methods).

Key changes being implemented are:

  • Giving additional weight to health benefits in the most severe conditions to allow more equitable access to treatments for these conditions, not just to treatments used at the end-of-life.
  • Adopting new approaches to the evidence NICE considers in its assessments. For example, NICE will expand on and improve how it considers real-world evidence from the lived experiences of patients.
  • Allowing more flexibility for NICE’s independent committees in cases where its particularly difficult to generate enough evidence. Sometimes, research into conditions affecting children, rare diseases or where the new treatment is innovative or complex can be problematic. The changes will allow NICE’s committees to consider uncertainty appropriately and to manage the risks to patients and the NHS while preventing inappropriate barriers to valuable innovations.
  • Adopting a clearer vision, principles and routing criteria for treatments for very rare diseases that NICE will evaluate under its Highly Specialised Technologies (HST) Programme. This will improve the efficiency, predictability and clarity when routing topics to the programme and build upon NICE’s ambition to provide fairer access to highly specialised medicines and treatments within the NHS.
  • Earlier engagement with NHS England and NHS Improvement and companies about commercial/managed access proposals that allow NHS patients to receive a treatment while further data is collected on its effectiveness. There will also be greater clarity around the circumstances in which NICE committees can make a managed access recommendation.

Professor Gillian Leng CBE, NICE chief executive, said: “Our vision at NICE is to be at the forefront of delivering access for patients in the NHS to valuable, evidence-based innovative medicines, medical devices and diagnostics. The changes that we are making will provide a robust foundation for our evaluations now and in the future and enable us to continue to lead the way in rapid, independent health technology assessments.

“But they are not the end of the story. In the short term, we will explore the impacts and benefits of the updated methods and processes. We need to ensure they are effectively implemented in order to realise the benefits for NICE, the NHS and the wider stakeholder community, as well as supporting the Government’s wider vision for life sciences.

“Going forward, NICE will adopt a more modular approach to updates to its methods and processes. This will enable us to be more agile and responsive, monitoring, reviewing and improving our methods and processes into the future, making sure they remain cutting edge as the healthcare landscape continues to evolve.”

- Advertisement -
Emma Cooper
Emma is Digital Editor at Pf.


- Advertisement -



Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription